Skip to main navigation Skip to search Skip to main content

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

  • Bruce A.C. Cree
  • , Douglas L. Arnold
  • , Robert J. Fox
  • , Ralf Gold
  • , Patrick Vermersch
  • , Ralph H.B. Benedict
  • , Amit Bar-Or
  • , Daniela Piani-Meier
  • , Nicolas Rouyrre
  • , Shannon Ritter
  • , Ajay Kilaru
  • , Goeril Karlsson
  • , Gavin Giovannoni
  • , Ludwig Kappos
  • University of California at San Francisco
  • McGill University
  • Cleveland Clinic Foundation
  • Ruhr University Bochum
  • Université de Lille
  • University of Pennsylvania
  • Novartis
  • Queen Mary University of London
  • University of Basel

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

Background: Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) patients in the Phase 3 EXPAND study. Objective: The aim of this study was to assess long-term efficacy and safety of siponimod 2 mg/day from the EXPAND study including the extension part, up to > 5 years. Methods: In the open-label extension part, participants receiving placebo during the core part were switched to siponimod (placebo-siponimod group) and those on siponimod continued the same treatment (continuous siponimod group). Results: Continuous siponimod reduced the risk of 6-month CDP by 22% (hazard ratio (HR) (95% confidence interval (CI)): 0.78 (0.66–0.92) p = 0.0026) and 6-month confirmed worsening in CPS by 23% (HR (95% CI): 0.77 (0.65–0.92) p = 0.0047) versus the placebo-siponimod group. Sustained efficacy on annualized relapse rate, total and regional brain atrophy, and inflammatory disease activity was also observed. No new, unexpected safety signals for siponimod were identified over the long term. Conclusion: The sustained efficacy and consistent long-term safety profile of siponimod up to > 5 years support its clinical utility for long-term treatment of SPMS. Benefits in the continuous siponimod versus placebo-siponimod group highlight the significance of earlier treatment initiation.

Original languageEnglish
Pages (from-to)1591-1605
Number of pages15
JournalMultiple Sclerosis Journal
Volume28
Issue number10
DOIs
StatePublished - Sep 2022

Keywords

  • Confirmed disability progression
  • S1P modulator
  • confirmed cognitive worsening
  • cortical gray matter
  • secondary progressive multiple sclerosis
  • siponimod

Fingerprint

Dive into the research topics of 'Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years'. Together they form a unique fingerprint.

Cite this